Herpes simplex research
Vaccine candidates
The chart below is an attempt to list all known proposed HSV and VZV vaccines and their characteristics. As of 2019, there are no HSV vaccines in production.

Herpes simplex research

Section Title: Vaccine candidates
Table Section Text: The chart below is an attempt to list all known proposed HSV and VZV vaccines and their characteristics. As of 2019, there are no HSV vaccines in production.

Vaccine	Company & Lead Researcher	Vaccine Type	Status	Trial Results

Zostavax (VZV, shingles)	Merck & Co.	Live-attenuated. This is primarily a vaccine focusing on Varicella zoster virus, not Herpes simplex virus.	In Production	Vaccination showed an immune response of 70% in 50 years old adults. The effectiveness went down to approx 64% in 60 years old, 41% in 70 years old, and 18% in 80 years old individuals.

Varivax, Varilrix(Varicella, C.Pox)	Merck & Co. & GlaxoSmithKline	Live-attenuated. This is primarily a vaccine focusing on Varicella zoster virus, not Herpes simplex virus.	In Production	One dose of vaccine prevents 95% of moderate disease and 100% of severe disease.

Shingrix, GSK1437173A (VZV, shingles)	GlaxoSmithKline	Subunit gE with AS01B/QS-21 adjuvant system. This is primarily a vaccine against Varicella zoster virus, not Herpes simplex virus.	In Production	Strong immune response in adults 65 and older. Final trials results reported an effectiveness of 90% in the first year, which went down slightly to 88% four years after vaccination.

Admedus HSV-2 therapeutic vaccine	Admedus Ian Frazer	DNA vaccine	Phase II	58% reduction in viral shedding, 81% reduction in outbreaks (post-booster). The booster further reduced outbreaks and shedding.

dl5-29 / ACAM-529 / HSV-529	Sanofi Pasteur David Knipe	HSV-2 replication-defective vaccine with UL5 and UL29 deleted	Phase I	HSV529 was safe, well-tolerated, immunogenic, eliciting significant neutralizing gD and ADCC-mediating antibodies. Modest cellular immune responses were observed only in HSV seronegative individuals.

VC2	Louisiana State University Gus Kousoulas	Live-attenuated HSV vaccine with small deletions in UL20 and UL53	Preclinical	The VC2 vaccine prevents HSV infection of neuronal axons and establishment of latency in animal models such as mice, guinea pig and rhesus monkeys.

R2	Thyreos LLC Gregory Smith, Gary Pickard, Ekaterina Heldwein	Live-attenuated HSV vaccine mutated in R2 coding region of UL37	Preclinical	A single-dose vaccine effective in mice and rats against multiple neuroinvasive herpesviruses including HSV.

HSV-2 ΔgD-2	Albert Einstein College of Medicine William Jacobs Jr & Betsy Harold	Live-attenuated HSV-2 vaccine with US6 (gD) deleted	Preclinical	Combats HSV-1 & HSV-2 in mice

HSV-2 Trivalent Vaccine	Perelman School of Medicine at the University of Pennsylvania Harvey Friedman & Sita Awasthi	HSV-2 subunit trivalent vaccine (containing gC2, gD2, gE2)	Preclinical	Reduced shedding to 0.2% in animals

G103	Immune Design	HSV-2 subunit trivalent vaccine (containing gD, pUL19, pUL25)	Preclinical	Prophylactic immunization completely protected against lethal intravaginal HSV-2 infection in mice

GV2207	GenVec	?	Preclinical	?

NE-HSV2	NanoBio	?	Preclinical	?

TBA	Profectus BioSciences	DNA vaccine	Antigen Discovery Stage	N/A

HSV-2 ICP0‾ HSV-2 0ΔNLS	Rational Vaccines RVx William Halford	Live-attenuated vaccine	Embroiled in patient consent controversy.	65% of the patients reported being free of symptoms.

Vitaherpavac & Herpovax	Russia	?	?	?

Sentence(s)

The dl5-29 vaccine is also known under the name ACAM-529 or HSV-529, which is a replication-defective vaccine.

final_sentence: The dl5-29 vaccine is also known under the name ACAM-529 or HSV-529, which is a replication-defective vaccine.